FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023698912> ?p ?o ?g. }

• W2023698912 endingPage "01" @default.
• W2023698912 startingPage "P4" @default.
• W2023698912 abstract "Abstract The aggressive triple negative breast cancers (TNBCs), which lack ER, PR and HER2, comprise a high-risk subset of human breast cancers which remain poorly characterized and lack effective treatments. While recent meta-analyses indicate the complexity of these tumors, no robust independently validated phenotypes have been defined. We have identified four distinct molecular subtypes through independent non-negative matrix factorization of expression data from 84 Discovery and 114 Validation Set TNBCs profiled at a single institution, with matching CNV data (SNP array). We then classified 485 publically available TNBCs via a centroid signature of only 80 genes. All three sets supported stratification of tumors by cell cycle, DNA repair, and immunological signaling pathways that have significantly different clinical outcomes. The first subtype, composed of intermediate grade tumors, resembles the “Molecular Apocrine” or “Luminal AR” subtype described previously and was defined by enrichment of prolactin, aryl hydrocarbon receptor, and ERBB4 signaling with activated downstream expression patterns of ESR1 signaling. Large deletions of chromosome 6 were specific to this subtype. While focal deletions at 14q21.2 and 12q13.13 were present in &gt;60% of tumors of the other subtypes, the genes at these loci (FOXA1 and ERBB3) were overexpressed in the first subtype. Inhibitors of AR and MUC1, both overexpressed, may prove effective for these tumors. A second subtype defined as “Claudin-Low” or “Mesenchymal Stem-Like” showed overexpression of markers of mesenchymal lineage (ADIPOQ and OGN). Targets responsive to beta-blockers (ADRB2), and targetable molecules associated with platelet and endothelial function (EDNRB, PLA2G2A, PTGER3/4, PTGFR, PTGFRA) were also upregulated. Two basal-like subtypes were found with significant differences in DFS and OS, even after correction for available clinical covariates. The high-risk (31% 5-year DFS), low immune function subtype was regulated by SOX 10, 8, and 6 and had unique copy-number driven expression of FGFR2. The second, low-risk (78% 5-year DFS) basal-like subtype was enriched for overexpression of many immune pathways, regulated by increased STAT1 and activated STAT downstream signaling, as well as exclusive upregulation of CTLA4. This subtype also had the lowest tumor cell fraction as calculated by allele specific copy number analysis of tumors (ASCAT). Both basal-like subtypes expressed TTK, CHEK1, TOP2A, and AURKA. CDK1 was correlated with copy number variation at 10q21.1. We proposed and validated four molecular subtypes of TNBC before applying the resulting gene signature to 7 external expression sets. The described subtypes vary by clinical behavior and inferred biology. Each subtype appears to have specific gene expression regulated by copy number variation and a set of genes targetable by currently available agents. These findings further define the heterogeneity of TNBCs and suggest potential therapeutic targets for each subtype. This work was supported by a Promise grant from the Susan G. Komen for the Cure Foundation (KG081694). Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-06-01." @default.
• W2023698912 created "2016-06-24" @default.
• W2023698912 creator A5001684597 @default.
• W2023698912 creator A5015213910 @default.
• W2023698912 creator A5015775418 @default.
• W2023698912 creator A5021701541 @default.
• W2023698912 creator A5037774999 @default.
• W2023698912 creator A5069866849 @default.
• W2023698912 creator A5080914070 @default.
• W2023698912 creator A5086475860 @default.
• W2023698912 creator A5089445907 @default.
• W2023698912 date "2013-12-15" @default.
• W2023698912 modified "2023-09-27" @default.
• W2023698912 title "Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes" @default.
• W2023698912 doi "https://doi.org/10.1158/0008-5472.sabcs13-p4-06-01" @default.
• W2023698912 hasPublicationYear "2013" @default.
• W2023698912 type Work @default.
• W2023698912 sameAs 2023698912 @default.
• W2023698912 citedByCount "2" @default.
• W2023698912 countsByYear W20236989122018 @default.
• W2023698912 countsByYear W20236989122020 @default.
• W2023698912 crossrefType "journal-article" @default.
• W2023698912 hasAuthorship W2023698912A5001684597 @default.
• W2023698912 hasAuthorship W2023698912A5015213910 @default.
• W2023698912 hasAuthorship W2023698912A5015775418 @default.
• W2023698912 hasAuthorship W2023698912A5021701541 @default.
• W2023698912 hasAuthorship W2023698912A5037774999 @default.
• W2023698912 hasAuthorship W2023698912A5069866849 @default.
• W2023698912 hasAuthorship W2023698912A5080914070 @default.
• W2023698912 hasAuthorship W2023698912A5086475860 @default.
• W2023698912 hasAuthorship W2023698912A5089445907 @default.
• W2023698912 hasConcept C104317684 @default.
• W2023698912 hasConcept C121608353 @default.
• W2023698912 hasConcept C127716648 @default.
• W2023698912 hasConcept C2781187634 @default.
• W2023698912 hasConcept C501734568 @default.
• W2023698912 hasConcept C502942594 @default.
• W2023698912 hasConcept C530470458 @default.
• W2023698912 hasConcept C54355233 @default.
• W2023698912 hasConcept C86803240 @default.
• W2023698912 hasConceptScore W2023698912C104317684 @default.
• W2023698912 hasConceptScore W2023698912C121608353 @default.
• W2023698912 hasConceptScore W2023698912C127716648 @default.
• W2023698912 hasConceptScore W2023698912C2781187634 @default.
• W2023698912 hasConceptScore W2023698912C501734568 @default.
• W2023698912 hasConceptScore W2023698912C502942594 @default.
• W2023698912 hasConceptScore W2023698912C530470458 @default.
• W2023698912 hasConceptScore W2023698912C54355233 @default.
• W2023698912 hasConceptScore W2023698912C86803240 @default.
• W2023698912 hasIssue "24_Supplement" @default.
• W2023698912 hasLocation W20236989121 @default.
• W2023698912 hasOpenAccess W2023698912 @default.
• W2023698912 hasPrimaryLocation W20236989121 @default.
• W2023698912 hasRelatedWork W1516968396 @default.
• W2023698912 hasRelatedWork W2009966535 @default.
• W2023698912 hasRelatedWork W2019988726 @default.
• W2023698912 hasRelatedWork W2088063203 @default.
• W2023698912 hasRelatedWork W2171277769 @default.
• W2023698912 hasRelatedWork W2185890143 @default.
• W2023698912 hasRelatedWork W2593242044 @default.
• W2023698912 hasRelatedWork W2916839585 @default.
• W2023698912 hasRelatedWork W4311220059 @default.
• W2023698912 hasRelatedWork W4367603427 @default.
• W2023698912 hasVolume "73" @default.
• W2023698912 isParatext "false" @default.
• W2023698912 isRetracted "false" @default.
• W2023698912 magId "2023698912" @default.
• W2023698912 workType "article" @default.